Short-term Effects of Eicosapentaenoic Acid on P Wave Signal-Averaged Electrocardiogram in Patients with Coronary Artery Disease by Kurisu, Satoshi et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Short-term Effects of Eicosapentaenoic Acid on P WaveSignal-Averaged Electrocardiogram in Patients with Coronary
Artery Disease
Auther(s) Kurisu, Satoshi; Kato, Yasuko; Mitsuba, Naoya; Ishibashi,Ken; Dohi, Yoshihiro; Nishioka, Kenji; Kihara, Yasuki
Citation International journal of cardiology , 154 (2) : 200 - 202
Issue Date 2012
DOI 10.1016/j.ijcard.2011.10.068
Self DOI
URL http://ir.lib.hiroshima-u.ac.jp/00034795
Right (c) 2012 Elsevier Ireland Ltd. All rights reserved.
Relation
Short-term Effects of Eicosapentaenoic Acid on P Wave Signal-Averaged 
Electrocardiogram in Patients with Coronary Artery Disease 
 
Department of Cardiovascular Medicine, Hiroshima University Graduate 
School of Biomedical Sciences, Hiroshima, Japan 
 
 
Satoshi Kurisu, Yasuko Kato, Naoya Mitsuba, Ken Ishibashi,  
Yoshihiro Dohi, Kenji Nishioka, Yasuki Kihara 
 
Short title: EPA and P-wave SAECG 
 
 
 
 
 
Correspondence to:  
Satoshi Kurisu, MD 
1-2-3, Kasumi-cho, Minami-ku, 
Hiroshima, 734-8551, Japan 
Phone:+81-82-257-5540 
Fax:+81-82-257-1569 
E-mail: skurisu@nifty.com 
 
 
 
 
The antiarrhythmic properties of n-3 polyunsaturated fatty acids (PUFAs) 
have been demonstrated in experimental models and in patients with 
coronary artery disease [1-6]. On the other hand, the signal-averaged 
electrocardiogram (SAECG) of the P waves has been used to predict the 
development of atrial fibrillation by measuring the filtered P wave duration 
(FPD) as an index of atrial conduction delay with high accuracy [7-10].  In 
this study, we assessed whether key long-chain n-3 PUFA, eicosapentaenoic 
acid (EPA) affected parameters of P wave SAECG in patients with coronary 
artery disease. 
 
The study population consisted of 27 patients with coronary artery disease 
who had episodes of suspected paroxysmal atrial fibrillation. They were 
treated with 1800 mg of EPA ethyl ester (EPADEL, Mochida Pharmaceutical, 
JAPAN) for 3 months [11,12]. Blood samples were collected before and 3 
months after the administration of EPA.  
Fatty acid analysis has been described in detail elsewhere [13-16]. Fatty acid 
composition in the methylated sample was analyzed by gas chromatography. 
We determined the levels of n-6 PUFAs (dihomo-γ-linolenic acid (DGLA) 
and arachidonic acid (AA)) and n-3 PUFAs (EPA and docosahexaenoic acid 
(DHA)). 
The P wave SAECGs were obtained with a multipurpose electrocardiograph 
(FDX-6531, Fukuda Denshi Co., Tokyo) before and 3 months after the 
administration of EPA. P wave triggering signals for 500 beats during sinus 
rhythm were integrated. The P wave complexes from the three bipolar leads 
were combined into a vector magnitude using the formula (X2+Y2+Z2)1/2. The 
onset and offset of the P waves were defined as the points where the voltage 
of the atrial signal exceeded 0.4 μV during the TP segment and returned to 
a level of 0.4 μV, respectively. The FPD and the root-mean-square voltage 
for the last 20 ms (RMS-20) in SAECG were measured in the vector 
magnitude.  
Data are expressed as means±SD. The paired Student t test was used to 
compare the two sequential values during follow-up. Differences were 
considered significant at p < 0.05. 
 
Patient characteristics are shown in Table 1. There were 18 male and 9 
female patients with a mean age of 69±10 years. Left ventricular ejection 
fraction was 57.2±10.7 %. Left atrial diameter was 39.2±5.1 mm. 
Serum lipid and PUFA levels before and after the treatment with EPA are 
shown in Table 2. The treatment with EPA increased the EPA level (51±18
μg/ml to 141±48μg/ml, p<0.001). On the other hand, it decreased the 
GDLA level (34±12μg/ml to 24±8μg/ml, p<0.001) and the DHA level (163
±38μg/ml to 143±36μg/ml, p<0.001).  
There was a significant correlation between left atrial diameter and FPD 
before the treatment with EPA (r=0.50, p<0.01, Figure 1). The treatment 
with EPA did not affect FPD  (122±22 ms to 123±20 ms, p=ns) as well as 
RMS-20 (5.12±3.21 μV to 5.12±3.00 μV, p=ns). 
 
This study demonstrated that short-term treatment with EPA significantly 
increased serum EPA level, but did not affect any parameter of P wave 
SAECG in patients with coronary artery disease. 
The concept that n-3 PUFAs may have antiarrhythmic effects for human 
atrium is supported by basic sciences. Li et al reported that EPA and DHA 
inhibit Ito, Ikur, and INa in human atrial myocytes using a whole-cell patch 
voltage clamp technique [17]. Kitamura et al recently investigated the effects 
of EPA on atrial fibrillation associated with heart failure in a rabbit model 
and demonstrated that EPA might prevent atrial remodeling through the 
suppression of fibrosis [18]. P wave SAECG has been demonstrated to 
correlate with direct intra-atrial electrocardiographic recording [19,20]. This 
good correlation supports the notion that FPD serves as a surrogate marker 
of atrial conduction time. Nomura et al previously evaluated P wave SAECG 
in hypertensive patients with paroxysmal atrial fibrillation, and 
demonstrated that there was a significant correlation between FPD and 
procollagen C propeptide type I as a marker of cardiac fibrosis [21]. On the 
basis of their results, we hypothesized that EPA might affect P wave SAECG 
in patients with coronary artery disease. This study showed that oral 
administration of EPA for 3 months did not affect PFD as well as RMS-20 of 
P wave SAECG. There are several possible reasons for this discrepancy 
between experimental and our clinical studies. First, in experimental studies, 
cardiac fibrosis was induced by rapid ventricular pacing in rabbits [18] or 
transverse aortic constriction in mice [22]. On the other hand, in our study, 
most patients had preserved systolic function despite of coronary artery 
disease, and about half of patients were receiving angiotensin-converting 
enzyme inhibitor or angiotensin II type 1 receptor blocker. These agents have 
been demonstrated to prevent cardiac fibrosis [21,23]. Thus, there was a 
possibility that atrial fibrosis was mild in our patients compared with those 
in experimental models. Second, in experimental studies, a dose of 300 
mg/kg per day was often administered [18]. This dose was markedly high 
compared with the usual dose in humans. A dose of 1800 mg per day has 
been demonstrated to prevent major coronary events in clinical studies [12], 
but might not be enough to prevent atrial fibrosis.  
There were several limitations in this study. First, we assessed the effect of 
EPA for 3 months, but long-term follow-up data were not obtained. Second, 
we did not assess the effect of higher doses of EPA. Finally, the small sample 
size is a major limitation and a larger study should be performed to confirm 
our findings. 
In conclusion, short-term treatment with EPA significantly increased serum 
EPA level, but did not affect any parameter of P wave SAECG in patients 
with coronary artery disease. 
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FIGURE LEGEND 
Figure 1 There was a significant correlation between left atrial diameter and 
filtered P wave duration before the treatment with EPA (r=0.50, p<0.01). 

Number of patients 27
Male gender 18 (67%)
Age (years) 69±10
Diabetes 10 (37%)
Hypertension 15 (56%)
Prior myocardial infarction 8 (30%)
Prior coronary intervention 17 (63%)
Medications
   ACE-I or ARB 13 (48%)
   Beta blocker 14 (52%)
   Calcium channel blocker 14 (52%)
   Aspirin 20 (74%)
   Warfarin 4 (15%)
   Statin 20 (74%)
Echocardiographic parameters
   Left ventricular end-diastolic diameter (mm 48.8±6.5
   Left ventricular end-systolic diameter (mm) 34.1±8.2
   Left ventricular ejection fraction (%) 57.2±10.7
   Left atrial diameter (mm) 39.2±5.1
Table 1 Baseline characteristics
ACE-I, angiotensin-converting enzyme inhibitor; 
ARB, angiotensin II type 1 receptor blocker.
Before After p value
EPA ethyl ester EPA ethyl ester
Low-density lipoprotein cholesterol (mg/dl) 96±31 92±30 ns
High-density lipoprotein cholesterol (mg/dl) 51±10 53±16 ns
Triglyceride (mg/dl) 147±78 137±87 ns
n-6 polyunsaturated fatty acid 
   Dihomo-γ-linolenic acid (μg/ml) 34±12 24±8 <0.001
   Arachidonic acid (μg/ml) 163±38 143±36 <0.001
n-3 polyunsaturated fatty acid 
   Eicosapentaenoic acid (μg/ml) 51±18 141±48 <0.001
   Docosahexaenoic acid (μg/ml) 130±37 118±46 ns
Ratio of EPA to AA 0.32±0.13 1.02±0.37 <0.001
P wave SAECG
   Filtered P wave duration (msec) 122±22 123±20 ns
   Root-mean-square voltage for the last 20 ms (μV 5.12±3.21 5.12±3.00 ns
Table 2 Serum lipid levels, polyunsaturated fatty acid levels and parameters of P wave SAECG
before and after the administration of EPA ethyl ester
EPA, eicosapentaenoic acid; AA, arachidonic acid; SAECG, signal averaged electrocardiogram. 
